Highlights
KLSE: GENTING (3182)       GENTING BHD MAIN : Consumer
Last Price Today's Change   Day's Range   Trading Volume
4.66   +0.07 (1.53%)  4.59 - 4.70  5,014,700
Analyze this stock with MQ Trader system

Financials


Market Cap: 18,066 Million

Market Cap 18,066 Million
NOSH 3,877 Million

Latest Audited Result:  31-Dec-2022

Latest Audited Result: 31-Dec-2022
Announcement Date 10-Mar-2023
Next Audited Result: 31-Dec-2023
Est. Ann. Date: 10-Mar-2024
Est. Ann. Due Date: 28-Jun-2024

Latest Quarter:  31-Dec-2022 [#4]

Latest Quarter: 31-Dec-2022 [#4]
Announcement Date 23-Feb-2023
Next Quarter: 31-Mar-2023
Est. Ann. Date: 26-May-2023
Est. Ann. Due Date: 30-May-2023
QoQ | YoY   -231.79%  |    -29.98%

Annual (Unaudited) ( EPS: -7.74, P/E: -60.24 )

Revenue | NP to SH 22,383,714  |  -299,909
RPS | P/RPS 577.36 Cent  |  0.81
EPS | P/E | EY -7.74 Cent  |  -60.24  |  -1.66%
DPS | DY | Payout % 15.89 Cent  |  3.41%  |  - %
NAPS | P/NAPS 8.17  |  0.57
YoY   78.10%
NP Margin | ROE 0.20%  |  -0.95%
F.Y. | Ann. Date 31-Dec-2022  |  23-Feb-2023

T4Q Result ( EPS: -7.74, P/E: -60.24 )

Revenue | NP to SH 22,383,714  |  -299,909
RPS | P/RPS 577.36 Cent  |  0.81
EPS | P/E | EY -7.74 Cent  |  -60.24  |  -1.66%
DPS | DY | Payout % 15.89 Cent  |  3.41%  |  - %
NAPS | P/NAPS 8.17  |  0.57
QoQ | YoY   -14.91%  |    78.10%
NP Margin | ROE 0.20%  |  -0.95%
F.Y. | Ann. Date 31-Dec-2022  |  23-Feb-2023

Annualized Result ( EPS: -7.74, P/E: -60.24 )

Revenue | NP to SH 22,383,714  |  -299,909
RPS | P/RPS 577.36 Cent  |  0.81
EPS | P/E | EY -7.74 Cent  |  -60.24  |  -1.66%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   -71.45%  |    78.10%
NP Margin | ROE 0.20%  |  -0.95%
F.Y. | Ann. Date 31-Dec-2022  |  23-Feb-2023


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2022 23-Feb-2023 31-Dec-2022 4 22,383,714 1,265,064 44,421 -299,909 616,096 31,690,436 - % 0.20% -0.95% 3,850,600 581.30 577.36 -7.79 -7.74 16.00 15.89 8.2300 8.17   -14.91%   78.10% 30-Dec-2022 4.48 0.77 -57.52 0.54 -1.74% 3.57% 4.71 0.81 -60.47 0.57 -1.65% 3.40%
31-Dec-2022 24-Nov-2022 30-Sep-2022 3 20,859,491 1,446,761 342,504 -260,996 693,108 32,383,545 - % 1.64% -0.81% 3,850,600 541.72 538.05 -6.78 -6.73 18.00 17.88 8.4100 8.35   64.42%   78.52% 30-Sep-2022 4.48 0.83 -66.10 0.53 -1.51% 4.02% 24-Nov-2022 4.48 0.83 -66.10 0.53 -1.51% 4.02%
31-Dec-2022 25-Aug-2022 30-Jun-2022 2 18,240,081 433,987 -342,869 -733,573 693,108 31,805,956 - % -1.88% -2.31% 3,850,600 473.69 470.48 -19.05 -18.92 18.00 17.88 8.2600 8.20   40.72%   26.72% 30-Jun-2022 4.54 0.96 -23.83 0.55 -4.20% 3.96% 25-Aug-2022 4.70 0.99 -24.67 0.57 -4.05% 3.83%
31-Dec-2022 26-May-2022 31-Mar-2022 1 15,490,326 -471,464 -1,052,169 -1,237,568 423,566 31,805,956 - % -6.79% -3.89% 3,850,600 402.28 399.55 -32.14 -31.92 11.00 10.93 8.2600 8.20   9.64%   -1.14% 31-Mar-2022 4.68 1.16 -14.56 0.57 -6.87% 2.35% 26-May-2022 4.88 1.21 -15.18 0.59 -6.59% 2.25%
31-Dec-2021 24-Feb-2022 31-Dec-2021 4 13,529,534 -970,782 -1,413,087 -1,369,646 423,566 31,805,956 - % -10.44% -4.31% 3,850,600 351.36 348.98 -35.57 -35.33 11.00 10.93 8.2600 8.20   -12.74%   -33.74% 31-Dec-2021 4.67 1.33 -13.13 0.57 -7.62% 2.36% 24-Feb-2022 4.50 1.28 -12.65 0.54 -7.90% 2.44%
31-Dec-2021 25-Nov-2021 30-Sep-2021 3 11,739,980 -980,379 -1,304,434 -1,214,864 327,301 32,152,511 - % -11.11% -3.78% 3,850,600 304.89 302.82 -31.55 -31.34 8.50 8.44 8.3500 8.29   -21.36%   -133.49% 30-Sep-2021 5.04 1.65 -15.97 0.60 -6.26% 1.69% 25-Nov-2021 4.94 1.62 -15.66 0.59 -6.39% 1.72%
31-Dec-2021 27-Aug-2021 30-Jun-2021 2 11,536,663 -642,033 -1,399,288 -1,001,057 327,301 32,614,583 - % -12.13% -3.07% 3,850,600 299.61 297.57 -26.00 -25.82 8.50 8.44 8.4700 8.41   18.19%   -1,093.61% 30-Jun-2021 4.93 1.65 -18.96 0.58 -5.27% 1.72% 27-Aug-2021 4.93 1.65 -18.96 0.58 -5.27% 1.72%
31-Dec-2021 25-May-2021 31-Mar-2021 1 9,707,909 -1,795,167 -2,265,431 -1,223,582 577,590 33,076,654 - % -23.34% -3.70% 3,850,600 252.11 250.40 -31.78 -31.56 15.00 14.90 8.5900 8.53   -19.47%   -193.99% 31-Mar-2021 5.03 2.00 -15.83 0.59 -6.32% 2.98% 25-May-2021 4.91 1.95 -15.45 0.57 -6.47% 3.05%
31-Dec-2020 25-Feb-2021 31-Dec-2020 4 11,564,060 -1,526,452 -2,073,977 -1,024,141 577,590 32,961,137 - % -17.93% -3.11% 3,850,600 300.32 298.28 -26.60 -26.42 15.00 14.90 8.5600 8.50   -96.84%   -151.31% 31-Dec-2020 4.46 1.49 -16.77 0.52 -5.96% 3.36% 25-Feb-2021 4.63 1.54 -17.41 0.54 -5.74% 3.24%
31-Dec-2020 26-Nov-2020 30-Sep-2020 3 13,819,008 -698,780 -1,294,185 -520,296 847,132 33,230,678 - % -9.37% -1.57% 3,850,600 358.88 356.45 -13.51 -13.42 22.00 21.85 8.6300 8.57   -520.37%   -124.52% 30-Sep-2020 3.18 0.89 -23.53 0.37 -4.25% 6.92% 26-Nov-2020 4.25 1.18 -31.45 0.49 -3.18% 5.18%
31-Dec-2020 27-Aug-2020 30-Jun-2020 2 15,815,173 195,229 -155,300 -83,868 847,132 34,231,835 - % -0.98% -0.25% 3,850,600 410.72 407.93 -2.18 -2.16 22.00 21.85 8.8900 8.83   -106.44%   -105.44% 30-Jun-2020 4.10 1.00 -188.24 0.46 -0.53% 5.37% 27-Aug-2020 3.54 0.86 -162.53 0.40 -0.62% 6.21%
31-Dec-2020 21-May-2020 31-Mar-2020 1 20,152,960 3,185,287 2,366,789 1,301,865 847,132 35,040,461 65.07% 11.74% 3.72% 3,850,600 523.37 519.82 33.81 33.58 22.00 21.85 9.1000 9.04   -34.77%   -1.71% 31-Mar-2020 3.75 0.72 11.09 0.41 9.02% 5.87% 21-May-2020 4.08 0.78 12.07 0.45 8.29% 5.39%
31-Dec-2019 27-Feb-2020 31-Dec-2019 4 21,616,543 4,582,582 3,681,095 1,995,823 847,132 35,348,509 42.45% 17.03% 5.65% 3,850,600 561.38 557.57 51.83 51.48 22.00 21.85 9.1800 9.12   -5.95%   46.15% 31-Dec-2019 6.05 1.08 11.67 0.66 8.57% 3.64% 27-Feb-2020 5.16 0.92 9.96 0.56 10.04% 4.26%
31-Dec-2019 28-Nov-2019 30-Sep-2019 3 21,710,965 4,592,126 3,980,184 2,122,162 750,867 34,809,423 35.38% 18.33% 6.10% 3,850,600 563.83 560.01 55.11 54.74 19.50 19.37 9.0400 8.98   37.74%   151.57% 30-Sep-2019 5.74 1.02 10.42 0.63 9.60% 3.40% 28-Nov-2019 5.85 1.04 10.61 0.65 9.42% 3.33%
31-Dec-2019 29-Aug-2019 30-Jun-2019 2 21,797,428 3,369,510 2,531,245 1,540,681 750,867 34,770,916 48.74% 11.61% 4.43% 3,850,600 566.08 562.24 40.01 39.74 19.50 19.37 9.0300 8.97   16.32%   17.56% 28-Jun-2019 6.77 1.20 16.92 0.75 5.91% 2.88% 29-Aug-2019 5.90 1.04 14.75 0.65 6.78% 3.31%
31-Dec-2019 23-May-2019 31-Mar-2019 1 21,175,018 3,157,028 2,297,791 1,324,517 826,264 34,110,998 62.38% 10.85% 3.88% 3,850,000 550.00 546.18 34.40 34.16 21.50 21.31 8.8600 8.80   -3.01%   -4.25% 29-Mar-2019 6.64 1.21 19.30 0.75 5.18% 3.24% 23-May-2019 6.33 1.15 18.40 0.71 5.43% 3.40%
31-Dec-2018 27-Feb-2019 31-Dec-2018 4 20,852,973 3,418,398 2,443,869 1,365,581 826,264 34,270,338 60.51% 11.72% 3.98% 3,850,600 541.55 537.88 35.46 35.22 21.50 21.31 8.9000 8.84   61.88%   -1.31% 31-Dec-2018 6.10 1.13 17.20 0.69 5.81% 3.52% 27-Feb-2019 7.32 1.35 20.64 0.82 4.84% 2.94%
31-Dec-2018 30-Nov-2018 30-Sep-2018 3 20,714,166 3,124,615 1,799,838 843,570 822,970 33,634,896 97.56% 8.69% 2.51% 3,839,600 539.49 534.30 21.97 21.76 21.50 21.23 8.7600 8.68   -35.63%   -64.77% 28-Sep-2018 7.81 1.45 35.55 0.89 2.81% 2.75% 30-Nov-2018 6.28 1.16 28.58 0.72 3.50% 3.42%
31-Dec-2018 29-Aug-2018 30-Jun-2018 2 20,372,289 4,212,026 3,067,416 1,310,496 822,970 33,564,816 62.80% 15.06% 3.90% 3,831,600 531.69 525.48 34.20 33.80 21.50 21.23 8.7600 8.66   -5.26%   -52.87% 29-Jun-2018 8.41 1.58 24.59 0.96 4.07% 2.56% 29-Aug-2018 8.70 1.64 25.44 0.99 3.93% 2.47%
31-Dec-2018 24-May-2018 31-Mar-2018 1 20,502,151 4,243,304 3,127,241 1,383,313 816,267 33,391,697 59.01% 15.25% 4.14% 3,829,323 535.40 528.83 36.12 35.68 21.32 21.05 8.7200 8.61   -0.03%   -48.12% 30-Mar-2018 8.73 1.63 24.17 1.00 4.14% 2.44% 24-May-2018 8.44 1.58 23.36 0.97 4.28% 2.53%
31-Dec-2017 27-Feb-2018 31-Dec-2017 4 20,019,594 4,258,674 3,184,999 1,383,671 816,267 33,777,124 58.99% 15.91% 4.10% 3,825,269 523.35 516.38 36.17 35.69 21.34 21.05 8.8300 8.71   -42.21%   -34.99% 29-Dec-2017 9.20 1.76 25.43 1.04 3.93% 2.32% 27-Feb-2018 8.99 1.72 24.85 1.02 4.02% 2.37%
31-Dec-2017 23-Nov-2017 30-Sep-2017 3 19,514,010 6,195,099 5,007,131 2,394,227 784,444 34,577,648 32.76% 25.66% 6.92% 3,799,741 513.56 503.34 63.01 61.76 20.64 20.23 9.1000 8.92   -13.89%   79.53% 29-Sep-2017 9.55 1.86 15.16 1.05 6.60% 2.16% 23-Nov-2017 9.15 1.78 14.52 1.01 6.89% 2.26%
31-Dec-2017 24-Aug-2017 30-Jun-2017 2 19,158,125 6,828,273 5,671,714 2,780,310 784,444 34,562,646 28.21% 29.60% 8.04% 3,752,730 510.51 494.16 74.09 71.71 21.00 20.23 9.2100 8.91   4.28%   148.09% 30-Jun-2017 9.41 1.84 12.70 1.02 7.87% 2.23% 24-Aug-2017 9.79 1.92 13.21 1.06 7.57% 2.15%
31-Dec-2017 29-May-2017 31-Mar-2017 1 18,430,738 6,446,694 5,424,068 2,666,145 465,462 33,503,442 17.46% 29.43% 7.96% 3,722,604 495.10 475.40 71.62 68.77 12.50 12.01 9.0000 8.64   25.26%   196.64% 31-Mar-2017 9.59 1.94 13.39 1.07 7.47% 1.30% 29-May-2017 9.73 1.97 13.59 1.08 7.36% 1.28%
31-Dec-2016 23-Feb-2017 31-Dec-2016 4 18,365,805 5,475,682 4,491,339 2,128,554 465,462 33,997,381 21.87% 24.45% 6.26% 3,723,700 493.21 473.72 57.16 54.90 12.50 12.01 9.1300 8.77   59.61%   53.35% 30-Dec-2016 8.00 1.62 14.00 0.88 7.15% 1.56% 23-Feb-2017 9.08 1.84 15.88 0.99 6.30% 1.38%
31-Dec-2016 24-Nov-2016 30-Sep-2016 3 18,532,172 3,450,038 2,711,048 1,333,602 130,077 32,547,195 9.75% 14.63% 4.10% 3,723,935 497.65 478.02 35.81 34.40 3.50 3.36 8.7400 8.40   19.00%   0.81% 30-Sep-2016 7.93 1.59 22.14 0.91 4.52% 0.44% 24-Nov-2016 8.06 1.62 22.51 0.92 4.44% 0.43%
31-Dec-2016 25-Aug-2016 30-Jun-2016 2 18,493,917 3,089,925 2,287,114 1,120,695 130,077 31,443,463 11.61% 12.37% 3.56% 3,716,721 497.59 477.03 30.15 28.91 3.50 3.36 8.4600 8.11   24.69%   -14.74% 30-Jun-2016 8.20 1.65 27.19 0.97 3.68% 0.43% 25-Aug-2016 8.21 1.65 27.23 0.97 3.67% 0.43%
31-Dec-2016 24-May-2016 31-Mar-2016 1 18,436,391 2,773,137 1,940,628 898,782 130,077 30,328,772 14.47% 10.53% 2.96% 3,716,761 496.03 475.55 24.18 23.18 3.50 3.36 8.1600 7.82   -35.25%   -44.47% 31-Mar-2016 9.80 1.98 40.53 1.20 2.47% 0.36% 24-May-2016 8.47 1.71 35.03 1.04 2.86% 0.41%
31-Dec-2015 23-Feb-2016 31-Dec-2015 4 18,100,356 3,445,997 2,597,677 1,388,012 130,077 32,630,984 9.37% 14.35% 4.25% 3,716,513 487.03 466.88 37.35 35.80 3.50 3.36 8.7800 8.42   4.92%   -7.23% 31-Dec-2015 7.34 1.51 19.65 0.84 5.09% 0.48% 23-Feb-2016 8.10 1.66 21.69 0.92 4.61% 0.43%
31-Dec-2015 26-Nov-2015 30-Sep-2015 3 17,802,962 3,632,499 2,654,336 1,322,902 111,466 32,242,131 8.43% 14.91% 4.10% 3,718,815 478.73 459.21 35.57 34.12 3.00 2.88 8.6700 8.32   0.64%   -22.46% 30-Sep-2015 7.27 1.52 20.44 0.84 4.89% 0.41% 26-Nov-2015 7.30 1.52 20.52 0.84 4.87% 0.41%
31-Dec-2015 26-Aug-2015 30-Jun-2015 2 17,649,838 3,508,437 2,567,341 1,314,505 111,466 28,685,057 8.48% 14.55% 4.58% 3,710,874 475.62 455.26 35.42 33.91 3.00 2.88 7.7300 7.40   -18.79%   -27.60% 30-Jun-2015 8.06 1.69 22.75 1.04 4.39% 0.37% 26-Aug-2015 6.64 1.40 18.74 0.86 5.33% 0.45%
31-Dec-2015 28-May-2015 31-Mar-2015 1 17,890,762 4,013,699 3,032,368 1,618,662 148,635 28,289,308 9.18% 16.95% 5.72% 3,717,386 481.27 461.47 43.54 41.75 4.00 3.83 7.6100 7.30   8.19%   -15.24% 31-Mar-2015 9.00 1.87 20.67 1.18 4.84% 0.44% 28-May-2015 8.50 1.77 19.52 1.12 5.12% 0.47%
31-Dec-2014 26-Feb-2015 31-Dec-2014 4 18,216,498 4,262,349 3,146,126 1,496,133 148,635 26,826,267 9.93% 17.27% 5.58% 3,715,549 490.28 469.87 40.27 38.59 4.00 3.83 7.2200 6.92   -12.31%   -17.34% 31-Dec-2014 8.87 1.81 22.03 1.23 4.54% 0.45% 26-Feb-2015 8.98 1.83 22.30 1.24 4.48% 0.45%
31-Dec-2014 21-Nov-2014 30-Sep-2014 3 17,998,827 4,451,878 3,480,484 1,706,131 37,169 25,829,978 2.18% 19.34% 6.61% 3,716,543 484.29 464.26 45.91 44.01 1.00 0.96 6.9500 6.66   -6.03%   -55.13% 30-Sep-2014 9.49 1.96 20.67 1.37 4.84% 0.11% 21-Nov-2014 9.40 1.94 20.48 1.35 4.88% 0.11%
31-Dec-2014 28-Aug-2014 30-Jun-2014 2 17,984,954 4,580,031 3,713,109 1,815,530 1,884,087 25,869,923 103.78% 20.65% 7.02% 3,716,942 483.86 463.90 48.84 46.83 51.00 48.60 6.9600 6.67   -4.93%   -49.84% 30-Jun-2014 9.99 2.06 20.45 1.44 4.89% 5.11% 28-Aug-2014 9.70 2.00 19.86 1.39 5.04% 5.26%
31-Dec-2014 29-May-2014 31-Mar-2014 1 17,890,067 4,875,165 3,941,081 1,909,759 1,846,918 26,025,838 96.71% 22.03% 7.34% 3,707,384 482.55 461.45 51.51 49.26 50.00 47.64 7.0200 6.71   5.51%   -48.21% 31-Mar-2014 10.00 2.07 19.41 1.42 5.15% 5.00% 29-May-2014 9.80 2.03 19.02 1.40 5.26% 5.10%
31-Dec-2013 27-Feb-2014 31-Dec-2013 4 17,111,661 4,344,226 3,705,102 1,810,066 1,846,918 25,299,715 102.04% 21.65% 7.15% 3,693,389 463.31 441.38 49.01 46.69 50.00 47.64 6.8500 6.53   -52.39%   -54.56% 31-Dec-2013 10.26 2.21 20.94 1.50 4.78% 4.87% 27-Feb-2014 10.08 2.18 20.57 1.47 4.86% 4.96%
31-Dec-2013 28-Nov-2013 30-Sep-2013 3 16,949,584 4,548,041 5,671,139 3,802,119 2,013,184 23,936,062 52.95% 33.46% 15.88% 3,693,836 458.86 437.19 102.93 98.07 54.50 51.93 6.4800 6.17   5.05%   66.72% 30-Sep-2013 10.40 2.27 10.10 1.60 9.90% 5.24% 28-Nov-2013 10.36 2.26 10.06 1.60 9.94% 5.26%
31-Dec-2013 29-Aug-2013 30-Jun-2013 2 16,676,789 4,269,416 5,380,736 3,619,436 166,266 23,314,749 4.59% 32.26% 15.52% 3,694,889 451.35 430.16 97.96 93.36 4.50 4.29 6.3100 6.01   -1.85%   39.30% 28-Jun-2013 10.44 2.31 10.66 1.65 9.38% 0.43% 29-Aug-2013 9.18 2.03 9.37 1.45 10.67% 0.49%
31-Dec-2013 30-May-2013 31-Mar-2013 1 16,681,985 4,367,965 5,483,220 3,687,689 295,562 22,459,191 8.01% 32.87% 16.42% 3,693,945 451.60 430.29 99.83 95.12 8.00 7.62 6.0800 5.79   -7.43%   34.74% 29-Mar-2013 10.02 2.22 10.04 1.65 9.96% 0.80% 30-May-2013 10.26 2.27 10.28 1.69 9.73% 0.78%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock with up to 3 x trading limit. Find out more.
  34 people like this.
 
nicholas99 go genting big/ small.
30/03/2023 3:00 PM
Michael_chan2022 For 2023, it's only one way... GenB up..up up
30/03/2023 3:19 PM
AngTayKor Yes @ElGato, ATK small fish follow the whales. TaiKor super nice guy n very helpful person. Besides those funds he is managing, he n family owns abt 1% of Taurx. But he always overly bullish, everytime after talking to him you wont want to sell your taurx shares. Ha!

TaiKor will try to arrange the best deal for Taurx to benchmark the highest price. Those deals rejected by Taurx will then flow to secondary market. But i think this China fund can easily absorb both Taurx's new issues + plenty of shares on secondary market.
30/03/2023 3:59 PM
James_Bond Genting, hv faith, you will be rewarded greatly! Cheers!
30/03/2023 7:16 PM
ClaraChan94 Reinvest Genting when gets dividend next month
30/03/2023 7:36 PM
AngTayKor Posted by MoneyMakers > 3 hours ago | Report Abuse
No use TauRx - alrdy fail experiment/placebo
Even latest fundraising undersubscribed - nobody want
------------------------

Aiyo got people really so stoopid ah? You smarter than billionaire investors?

Taurx rights issue was fully subscribed. GenB (LKT) even applied for excess rights else all the excess rights will be gobbled up by Chinese billionaire underwriter.
30/03/2023 9:04 PM
AngTayKor Posted by Mikecyc > 10 hours ago | Report Abuse
Haha Tin Kosong MonieM give lectures here ke …no more Shouting Rocket Limit Up ke as in Tsh .. don’t own deleted own posts loh …hahaha
--------------------------

@MM your enemy ah? Aiyo enemies chasing after you until coming into GenB forum. You must be spewing a lot of rubbish everywhere in i3. Tsk Tsk Tsk....
30/03/2023 9:13 PM
AngTayKor Posted by AngTayKor > 2022-11-07 15:54 | Report Abuse
TauRx Warrants Exercise
The latest results:-
1) 99.34% subscribed
2) amount raised = USD119.281 million.
------------------------------
Posted by MoneyMakers > 6 hours ago | Report Abuse
No use TauRx - alrdy fail experiment/placebo
Even latest fundraising undersubscribed - nobody want
------------------------------
Posted by MoneyMakers > 28 minutes ago | Report Abuse
Fact: TauRx reported only 99% warrant exercised (undersubscribed)
AngTK pls tell LKT or whichever chinese billionaire - still got 1% shares havent ‘gobble up’ kikiki
------------------------------


Aiyo really got people so dumb? Those attached piggyback warrants are non-transferable hence cannot be gobbled up by the underwriter. Its 99.34% VS 0.66%. Got 99.34% of warrant holders want. How can you say nobody want? Those 0.66% that failed to pay up on due date, its even better for other existing shareholders because less dilution at cheap price. ATK and many others also salivating want to gobble up those 0.66% warrant shares @USD45 each but legally unable to execute it. We are now talking abt issuing new shares at USD300/share. Those 0.66% that didnt pay up on due date too bad for them missed the golden huat opportunity to profit a few folds within a few months.

31/03/2023 12:19 AM
AngTayKor https://bm.cnfic.com.cn/sharing/share/articleDetail/165072276/1

@Michael your Chinese very good this article for you from the main news agency in China XinHua. Taurx got chance to get C.A in China also.
31/03/2023 12:43 AM
ElGato @ATK Very hopeful for CA in China especially with Xinhua News pushing for us.
31/03/2023 1:22 AM
AngTayKor Yes. All the best to Taurx and GenB shareholders. We will clear all the hurdles! MCI patient group average score 20% reversal (improvement) from initial baseline on a phase 3 trial is God's gift to mankind to defeat this devastating AD.
31/03/2023 1:56 AM
Michael_chan2022 Great to see more TauRx's news. Anxiously waiting for the re-rating of Genting TP. @ATK, thanks for sharing good news...
Let's all huat together. Cheers!
31/03/2023 8:59 AM
Mikecyc Haha no worries, a few years back , one of Genting Marketing Manager said the Income during the CNY 15 Days can cover 1 Year expenditures, foreseen Shl be improving …
31/03/2023 9:14 AM
James_Bond Go go go Genting… loving you! Cheers!
31/03/2023 9:21 AM
James_Bond Those who cut loss from Genting, please seek compensation from AngTayKor, Bob etc… hahaha…. I m right again! Cheers!
31/03/2023 10:47 AM
AngTayKor Posted by James_Bond > 4 minutes ago | Report Abuse
Those who cut loss from Genting, please seek compensation from AngTayKor, Bob etc… hahaha…. I m right again! Cheers!
------------------------

Loser Justborn dont anyhow put words into ATK's mouth. ATK did not say nasty things abt GenB or tell people here to cutloss. Go n check back the records posted here. Justborn you have no credibility here n serious character problem. Justborn is a shameless Liar, Fraud, Loser.
31/03/2023 10:58 AM
MoneyMakers Aiyoyo AngTK obviously ‘nobody want’ = joke..main point is undersubscribe

This what happens when no life/friends - cannot understand joke

P/s: warrant usd45 ‘undersubscribe’ alrdy proof TauRx not worth usd300/share
31/03/2023 11:18 AM
MoneyMakers TauRx alrdy fail experiment/placebo - yet still try get approval

Approval fail = more fundraising (if can find @ alrdy multiple experiment fail) or abandon proj

Want invest GenT better dont look TauRx - focus postpandemic travel better
31/03/2023 11:24 AM
James_Bond Clearly see AngTayKor is not gentleman! Haha…
31/03/2023 11:28 AM
Peaches L If everyone here is truly a genuine Gent shareholder, u shud b happy for one another whether it’s TauRx or any other relevant news/information. Why behaving like dog bite dog bone kinda low and childish mentality? Promoting TauRx here benefits Gent shareholders as well. Tis platform shud b a harmonious place for all interested parties to share relevant and useful information for benefit of Gent shareholders primarily. Haiya… lose money quarrel, make money oso quarrel. Family with no peace and harmony disrupts good chi and feng sui energy.
31/03/2023 11:33 AM
James_Bond Marvelous Genting! Loving you!
31/03/2023 11:33 AM
novel23 thx @ATK sharing TauRX update. hope for approval soon.
31/03/2023 11:39 AM
casanwk Prior high - 463 - been broken.
Is time to ride 3 wave ( minicycle)...
31/03/2023 11:41 AM
Peaches L Yeah, TQVM @ATK for yr kindness to share TauRx’s latest developments w us. I appreciate you.
31/03/2023 11:42 AM
MoneyMakers Not good overhype TauRx leh

Better give accurate TauRx info (even if bad news)
31/03/2023 11:47 AM
Michael_chan2022 Son needs support, it's falling behind.. :)
31/03/2023 12:27 PM
Michael_chan2022 Very soon, 4 series will be history
31/03/2023 12:40 PM
AngTayKor Posted by James_Bond > 1 hour ago | Report Abuse
Clearly see AngTayKor is not gentleman! Haha…
------------------------------

Aiya obviously Justborn not happy with ATK hence keep cursing and falsely accusing ATK for all sorts of bad things. ATK was the first here to point out his 90m rupiah Casino Royale Fund is a fraud to fool the naive. From 5.00 kept on buying and supporting but price crashed below 4.50. 2 weeks ago after Justborn declared he had enough GenB shares and will will stop buying, price started to rally. Real 90m fund or fraud? You decide for yourself la.
31/03/2023 12:52 PM
AngTayKor Posted by MoneyMakers > 1 hour ago | Report Abuse
Not good overhype TauRx leh
Better give accurate TauRx info (even if bad news)
----------------------------

The bad news is, some funds only offered a low ball offer price to buy Taurx shares, which makes ATK's Taurx shares worth only USD30m.

The good news is, if big China Fund comes in and buy Taurx shares, ATK's Taurx shares will be worth USD58.5M (5% sold liow).

I dont have over rm90m cash la. There is only one liar, fraud and loser here that declared he has over rm90m cash. Hahaha.
31/03/2023 1:10 PM
DestinyL ATK, the China 3rd phase trial only recently started? Estimated trial period until?
31/03/2023 1:31 PM
1invest1 Thanks @Mikecyc for sharing info.
Haha Tin Kosong MonieM give lectures here ke …no more Shouting Rocket Limit Up ke as in Tsh .. don’t own deleted own posts loh …hahaha

Haha no worries, a few years back , one of Genting Marketing Manager said the Income during the CNY 15 Days can cover 1 Year expenditures, foreseen Shl be improving …
31/03/2023 1:58 PM
1invest1 Tks @Peaches L.
for your post for ALL in GB forum.

If everyone here is truly a genuine Gent shareholder, u shud b happy for one another whether it’s TauRx or any other relevant news/information. Why behaving like dog bite dog bone kinda low and childish mentality? Promoting TauRx here benefits Gent shareholders as well. Tis platform shud b a harmonious place for all interested parties to share relevant and useful information for benefit of Gent shareholders primarily. Haiya… lose money quarrel, make money oso quarrel. Family with no peace and harmony disrupts good chi and feng sui energy.
31/03/2023 2:02 PM
1invest1 @AngTayKor, your posts are valued by

@Michael_chan2022,
@novel23,
@Peaches L,
@1invest1 and others.
31/03/2023 2:05 PM
AngTayKor Posted by AngTayKor > 1 month ago | Report Abuse

Firstly, we need to understand with Lucidity's placebo fiasco, full approval is not possible. What we are looking for is Conditional Approval (CA), meaning the regulators agree to let us commercialise HMTM pending results of a new retrial. Usually CA duration is abt 8 yrs (Aduhelm has it for 9 years). The trial design has to be approved by both EMA and FDA otherwise we will be doing 2 trials to satisfy each of them. These days regulators are getting strict with this CA loopholes because some drug companies didnt even do their retrial, some dragged their feet slowly for the trial to max out the CA duration while milking $ selling their drugs, some trials even failed but still selling refuse to pull off from the shelves. Regulators were weak in enforcing such CA approvals but they are getting their acts together now. FDA allows immediate commercialisation upon CA hence subject to a lot of system abuse by pharmas but they are trying to close many loopholes now. I think EMA is currently handling such system abuse better. They will only give the CA licence to commercialise the drug when the agreed retrial has reached full enrollment (all the patients has done their first-time-first-visit at the trial centres). I can talk all day here so better give short answer.

Taurx will submit document to FDA and EMA in March. Thereafter at least 6 months for approval, I suspect more likely 12 months or longer to know the outcome. Taurx have already submitted or submitting soon for some smaller countries for CA. Smaller countries that give fast track probably can get CA faster. Sandy Kingdom, UK, etc. Some some countries' CA may come soon, some later this year.

On the China side, Taurx has cancelled study TRx-237-801 (suppose to be a parallel trial with Lucidity) with the National Medical Products Administration (NMPA). Post Lucidity result, Taurx will be discussing with them on China CA and non-placebo new trial design as the drug can work but the trial did not work under Lucidity's trial design.
---------------------------------


@DestinyL, not so fast yet. Still discussing with China NMPA on HMTM's C.A. and new non-placebo trial design in China. Meanwhile Biogen/Eisai has obtained fast track review for approval in China. But I think their approval wont be smooth eventually as the Chinese regulators are fully aware of Lecanemab's super low drug efficacy (27% slowdown in decline compared to placebo's decline) that comes with high risk of brain swelling/bleeding including numerous death cases.

31/03/2023 2:12 PM
Michael_chan2022
wow...! GenS share price keeps moving Up! 天空才是它的极限...
31/03/2023 3:02 PM
Michael_chan2022
GenB go..go go
Cheers!
31/03/2023 3:07 PM
MoneyMakers Eisai didnt fail experiment - TauRx fail experiment/placebo

Aduhelm effectiveness questionable (like TauRx) but approved by FDA - Aduhelm 2022 sales only usd5Mil

** Approval doesnt mean boombastic sales - Dr wont recommend if questionable treatment or got other/better alternative
31/03/2023 3:33 PM
MoneyMakers Aduhelm (FDA approved) only got usd5Mil sales - US known expensive medical cost

TauRx in China will earn much less - cheap healthcare
31/03/2023 3:52 PM
James_Bond Am earning more with GenS… +25% now… haha…
31/03/2023 4:20 PM
Michael_chan2022 Sembcorp u96 more solid..
31/03/2023 4:36 PM
MoneyMakers Ding3 4.66 (+9sen div) highest monthly closing!!

Rebounding nicely from banking panic (panic sell GenT 4 no reason)

Slow steady back to rm5
31/03/2023 5:10 PM
ClaraChan94 Momentum seems like to have recovered for Genting
31/03/2023 6:01 PM
Michael_chan2022 https://www.sinchew.com.my/?p=4580476

Maybe Anwar bring good news for GenB.. let's see
31/03/2023 7:52 PM
RWG anwar will allow open 10 more casino in msia
31/03/2023 8:01 PM
newbie2019 Good one Peaches L….. what I felt too…. Happy weekend guys….
31/03/2023 8:47 PM
RWG https://www.sinchew.com.my/20230331/%e5%80%aa%e5%8f%af%e6%95%8f%ef%bc%9a%e6%8e%a5%e5%8f%97%e5%ae%89%e5%8d%8e%e9%82%80%e8%af%b7-%e4%b9%a0%e8%bf%91%e5%b9%b3%e5%b0%86%e5%9b%9e%e8%ae%bf%e9%a9%ac/
01/04/2023 10:20 AM
Michael_chan2022 https://news.cgtn.com/news/2023-03-31/Xi-Jinping-meets-Malaysian-prime-minister-1iCOLNKBqdq/index.html

Xi's meeting with Anwar opens new chapter in China-Malaysia relations

China funds pouring in.. Hou seh liao!
01/04/2023 11:36 AM
Michael_chan2022 https://www.channelnewsasia.com/commentary/malaysia-singapore-relations-anwar-unity-government-3387506?cid=internal_sharetool_androidphone_01042023_cna

Anwar's unity government may write a new chapter for Malaysia-Singapore relations

Temasek's fund lai liao..

2023 could be a good year for KLCI. Huat AAAAA!
01/04/2023 11:41 AM
Serious Beijing pledges RM170 bil investments in Malaysia: Anwar
This a result of 19 MoUs inked, round-table with Chinese business leaders, says PM
01/04/2023 4:32 PM
Michael_chan2022
https://youtu.be/zH31FGbZtvQ


wow! Good news keep coming.. 你播种了吗? Cheers!
02/04/2023 8:49 AM